Registered title, quoted from ClinicalTrials.gov
BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Soochow University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07854652, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
14 years to 75 years; sex: all
Registered eligibility fields
Relapsed/refractory disease: relapse, refractory disease, or disease progression after at least one line of systemic anti-leukemia therapy, with evaluable bone marrow and ≥5% blasts/lymphoblasts at screening; or
Inclusion criterion 6
Morphologic remission with MRD positivity: achievement of CR, CRh, or CRi after at least one course of standard induction or salvage therapy, with flow cytometry MRD ≥0.01% and/or MEF2D fusion transcript/ABL1 ≥0.1% at screening.
Inclusion criterion 7
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Inclusion criterion 9
Total bilirubin ≤1.5 × ULN; ≤3 × ULN is permitted for Gilbert syndrome;
Inclusion criterion 14
Creatinine clearance ≥50 mL/min;
Inclusion criterion 15
Pregnancy or breastfeeding.
Exclusion criterion 15
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07854652, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntary participation in the study and provision of written informed consent. For participants aged 14-17 years, written informed consent must be provided by a legal guardian, together with the participant's assent or confirmation as required by the ethics committee.
- Age ≥14 years and ≤75 years at the time of informed consent, regardless of sex.
- Diagnosis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) based on morphology, immunophenotyping, and clinical assessment.
- Prior clinical testing suggesting MEF2D rearrangement, with confirmation of the MEF2D rearrangement and its specific fusion partner during screening by RNA sequencing or a targeted RNA fusion panel.
- Meets either of the following baseline disease-status criteria:
- Relapsed/refractory disease: relapse, refractory disease, or disease progression after at least one line of systemic anti-leukemia therapy, with evaluable bone marrow and ≥5% blasts/lymphoblasts at screening; or
- Morphologic remission with MRD positivity: achievement of CR, CRh, or CRi after at least one course of standard induction or salvage therapy, with flow cytometry MRD ≥0.01% and/or MEF2D fusion transcript/ABL1 ≥0.1% at screening.
- Bone marrow morphology, flow cytometry MRD, and quantitative RT-qPCR for the MEF2D fusion transcript are all performed during screening and meet the applicable baseline stratification and enrollment requirements. Participants in MLFS are not eligible through the MRD-positive pathway.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Estimated life expectancy >12 weeks.
- Peripheral blood white blood cell count <25 × 10\^9/L before the first dose of ifupinostat hydrochloride; cytoreduction during screening is permitted to achieve this threshold.
- Adequate organ function:
- ALT and AST ≤2.5 × ULN; values up to ≤5 × ULN may be permitted when abnormalities are attributable to leukemic hepatic involvement, prior therapy, or another controllable cause, at the investigator's discretion;
- Total bilirubin ≤1.5 × ULN; ≤3 × ULN is permitted for Gilbert syndrome;
- Creatinine clearance ≥50 mL/min;
- Left ventricular ejection fraction (LVEF) ≥45%.
- No active central nervous system leukemia on cerebrospinal fluid examination during screening.
- Prior therapy meets the protocol-specified washout requirements, and acute non-hematologic toxicities have recovered to CTCAE Grade 0-1, baseline, or a clinically stable level. Reductions in ANC, hemoglobin, or platelet count attributable to leukemia or prior therapy are not exclusionary.
- Participants of childbearing potential agree to use effective contraception during study treatment and for the protocol-specified period after the last dose.
Exclusion Criteria:
- Isolated extramedullary relapse, or active extramedullary leukemia without bone marrow disease meeting one of the protocol-defined enrollment pathways.
- Active central nervous system leukemia.
- Failure to confirm MEF2D rearrangement during screening.
- White blood cell count ≥25 × 10\^9/L before the first dose despite cytoreduction, or an unacceptable risk of leukostasis, tumor lysis syndrome, severe infection, severe bleeding, or other acute complications as judged by the investigator.
- Inadequate washout from prior therapy:
- Chemotherapy, radiotherapy, immunotherapy, or other clearly anti-leukemia treatment within 14 days;
- Small-molecule investigational or targeted therapy within 14 days or 5 half-lives, whichever is shorter;
- Large-molecule therapy within 28 days or 5 half-lives, whichever is shorter;
- CAR-T therapy or autologous transplantation within 60 days with ongoing active CRS, ICANS, or uncontrolled toxicity;
- Allogeneic transplantation within 100 days, or active graft-versus-host disease or ongoing systemic immunosuppressive therapy.
- Uncontrolled active infection, active invasive fungal infection, active tuberculosis, sepsis, or septic shock.
- Uncontrolled HBV, HCV, or HIV infection; active syphilis; or active EBV- or CMV-related organ disease.
- Screening QTcF >450 ms in males or >470 ms in females; congenital long QT syndrome; clinically significant arrhythmia; or requirement for continued use of an irreplaceable medication known to prolong the QT interval.
- Uncontrolled or clinically significant cardiovascular disease, including recent myocardial infarction, unstable angina, severe heart failure, or severe arrhythmia.
- Pregnancy or breastfeeding.
- Known hypersensitivity to ifupinostat or any component of the formulation.
- Inability to avoid strong CYP3A4 inducers, or requirement for long-term use of strong CYP3A4 inhibitors or QT-prolonging drugs that cannot be safely managed.
- Another malignancy that may interfere with assessment of efficacy or safety in this study, except for malignancies considered cured and at low risk of recurrence at the investigator's discretion.
- Psychiatric, cognitive, or compliance-related problems that prevent adequate understanding of or adherence to study requirements.
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Quoted from ClinicalTrials.gov, NCT07854652, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07854652, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.